Sera Prognostics revenue SERA

Sales by quarter and over the last twelve months, from 2020.

Sera Prognostics' revenue was $70K over the twelve months to Jun 30, 2026, down 35% on a year earlier.

In its latest quarter, Q2 FY26, it was $30K, up 76% on the same quarter a year before.

Over the five fiscal years to FY2025 it grew 27% a year on average.

Revenue over time

Each fiscal year is the twelve months to its fourth quarter.

Quarter	Ended	Revenue	On a year earlier	Last 12 months
Q2 FY26	Jun 30, 2026	$30K	+76%	$70K
Q1 FY26	Mar 31, 2026	$14K	−63%	$57K
Q4 FY25	Dec 31, 2025	$10K	−58%	$81K
Q3 FY25	Sep 30, 2025	$16K	−45%	$95K
Q2 FY25	Jun 30, 2025	$17K	−29%	$108K
Q1 FY25	Mar 31, 2025	$38K	n/a	$115K
Q4 FY24	Dec 31, 2024	$24K	−41%	$77K
Q3 FY24	Sep 30, 2024	$29K	−31%	$94K
Q2 FY24	Jun 30, 2024	$24K	−80%	$107K
Q1 FY24	Mar 31, 2024	$0	−100%	$206K
Q4 FY23	Dec 31, 2023	$41K	−37%	$306K
Q3 FY23	Sep 30, 2023	$42K	−52%	$330K

Companies in Healthcare nearest Sera Prognostics' size, closest first, today.

Company	Revenue, 12 months	Growth
SERASera Prognostics	$70K	−35% a year
LFVNLifevantage	$182.6M	−20% a year
ICCCImmucell	$30.7M	+8% a year
KEQUKewaunee Scientific	$277.2M	+5% a year
SPROSpero Therapeutics	$47M	−3% a year
APTAlpha Pro Tech	$61.9M	+6% a year
ATNMActinium Pharmaceuticals	n/m
NEPHNephros	$20.7M	+24% a year
PDEXPro DEX	$77.5M	+16% a year
PLXProtalix BioTherapeutics	$80.6M	+30% a year
NATRNatures Sunshine Products	$492M	+7% a year
Peer median	$77.5M